Immunotherapeutic strategies using ADCs, bispecific T-cell engagers (BiTEs), and chimeric antigen receptor (CAR) T-cell therapy have shown great success in B-cell lymphoid leukemia and lymphoma due to the consistently expressed, safe and effective targets CD19 and/or CD22 (31–34). Here, CD19 is linked to lymphoma.